Free tool
FAERS Monitor: Tryngolza (Autoinjector)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218614 or its brand name (Tryngolza (Autoinjector), Olezarsen Sodium). Reports on generic versions are filed under their own applications.
Reports
947
Serious
201
21% of reports
Hospitalization
131
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain84
- blood triglycerides increased82
- injection site erythema77
- product dose omission issue63
- off label use57
- arthralgia40
- nausea36
- pancreatitis35
- pancreatitis acute34
- injection site swelling33
- fatigue30
- injection site rash30
- blood glucose increased29
- injection site bruising29
- abdominal pain27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 152 |
| 2026 | 795 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,212 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood triglycerides increasedSignal | 82 | 103.6 | 84.2 | 8,196 |
| pancreatitis acuteSignal | 34 | 33.6 | 24.2 | 1,044 |
| injection site rashSignal | 30 | 21.7 | 15.3 | 573 |
| pancreatitisSignal | 35 | 14.7 | 10.6 | 435 |
| injection site erythemaSignal | 77 | 13.8 | 11.1 | 906 |
| injection site swellingSignal | 33 | 9.6 | 6.8 | 246 |
| injection site bruisingSignal | 29 | 8.1 | 5.6 | 173 |
| injection site painSignal | 84 | 6.1 | 5.0 | 357 |
| product dose omission issueSignal | 63 | 4.8 | 3.7 | 186 |
| blood glucose increasedSignal | 29 | 3.4 | 2.4 | 48 |
| abdominal painSignal | 27 | 2.6 | 1.8 | 25 |
| arthralgiaSignal | 40 | 2.1 | 1.6 | 24 |
| off label use | 57 | 1.4 | 1.1 | 8 |
| nausea | 36 | 1.0 | 0.7 | 0 |
| fatigue | 30 | 0.9 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.